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Previous studies have demonstrated the ability of reprogramming endochondral bone into induced pluripotent stem (iPS) cells, but
whether similar phenomenon occurs in intramembranous bone remains to be determined. Here we adopted ﬂuorescence-activated
cell sorting-based strategy to isolate homogenous population of intramembranous calvarial osteoblasts from newborn transgenic
mice carrying both Osx1-GFP::Cre and Oct4-EGFP transgenes. Following retroviral transduction of Yamanaka factors (Oct4,
Sox2, Klf4, and c-Myc), enriched population of osteoblasts underwent silencing of Osx1-GFP::Cre expression at early stage of
reprogramming followed by late activation of Oct4-EGFP expression in the resulting iPS cells. These osteoblast-derived iPS cells
exhibited gene expression proﬁles akin to embryonic stem cells and were pluripotent as demonstrated by their ability to form
teratomas comprising tissues from all germ layers and also contribute to tail tissue in chimera embryos. These data demonstrate
that iPS cells can be generated from intramembranous osteoblasts.
1. Introduction
Bone constitutes a major part of the skeletal system that pro-
vides support and physical protection to various organs of
our body. During development, embryonic stem cells (ESCs)
give rise to three germ layers in which the mesoderm is a
major source of the mesenchymal precursors giving rise to
most of the bony skeleton via the formation of cartilage inter-
mediate in a process called endochondral ossiﬁcation. In
contrast, intramembranous ossiﬁcation involves direct con-
version of mesenchymal tissue into bone and primarily con-
tributes to the formation of the skull bones [1]. However,
these undiﬀerentiated mesenchyme cells are originated from
cranial neural crest cells, which are ectomesenchymal cells
arising from the crests of the neural folds. After delamination
from the neural folds, cranial neural crest-derived mesen-
chyme cells migrate to the destined regions where they
undergo condensation to produce osteoblasts, committed
bone precursor cells [2]. The osteoblasts are responsible for
the formation, deposition, and mineralization of the bone
extracellular matrix. Extrinsic and intrinsic regulators have
been deﬁned to regulate diﬀerent stages of osteoblast devel-
opment from its initial speciﬁcation to the production and
calciﬁcation of bone matrix [3]. These studies provide
important insight into the key molecules for the formation
of bone tissue during development and also derivation of
osteoblasts from various cell sources for therapeutic treat-
ment of bone defects.
Although bone possesses cell intrinsic capacity to regen-
erate, minor injury, aging, or trauma always results in signif-
icant bone loss that precludes natural replacement of bone
tissue. This can be resolved by autologous bone graft using
patient’s own healthy bone to replace missing bone, but this
surgical procedure is always associated with severe pain at
the site of removal and donor site morbidity [4]. In addition,
allogenic bone grafts carry the potential risks of pathogen
transmission from donor to recipient and immune rejection
[5]. Adult bone marrow-derived mesenchymal stem cells
(MSCs) provide a promising cell source for bone regenera-
tion because of their inherent capacity to diﬀerentiate into
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an osteogenic lineage as well as potent paracrine anti-
inﬂammatory properties [6]. However, the use of MSCs in
bone regeneration may be limited by their extreme low yield
(typically 0.001%–0.01%) obtained from bone marrow aspi-
rates and their proliferative potential, which signiﬁcantly
decreases with age [7]. These signiﬁcant limitations can be
resolved by transcription factor-mediated reprogramming
of embryonic skin ﬁbroblasts into patient-speciﬁc induced
pluripotent stem (iPS) cells [8], which have been shown to
provide unlimited source of MSCs for the generation of func-
tional osteoblasts both in vitro and in vivo [9]. Subsequent
studies further revealed that bone marrow cells [10], adult
liver and stomach cells [11], pancreatic cells [12], adult neu-
ral stem cells [13], and mature B lymphocytes [14], keratino-
cytes [15], and blood cells [16] can also be reprogrammed
into iPS cells. It is tempting to speculate that these iPS cells
derived from various cell sources could be diﬀerentiated into
osteoblasts under appropriate culture conditions [9, 17–19].
Therefore, diﬀerent lineages either at their progenitor or at
terminally diﬀerentiated state can be subjected to cell fate
conversion into pluripotent cells. Consistent with this notion,
a recent report added human osteoblasts (hOBs) as an addi-
tional source of cells to be reprogrammed into iPS cells which
diﬀerentiated into ectodermal and mesodermal cells but
exhibited low capacity to form endodermal cells upon cul-
tured in diﬀerentiation medium [20]. In this study, hOBs
were extracted from iliac crest bone, which is generated by
endochondral ossiﬁcation. Whether intramembranous bone
could also be reprogrammed into iPS cells remains to be
determined. In addition, this study did not demonstrate the
stepwise reprogramming process from osteoblasts into iPS
cells and the pluripotent potential of hOB-iPS cells in vivo.
Here we isolated a pure population of osteoblasts from
intramembranous bone of neonatal mice carrying both
Osx1-GFP::Cre and Oct4-EGFP transgenes. Daily monitoring
of the reprogramming process revealed initial silencing of
Osx1-GFP::Cre transgene expression followed by late activa-
tion of Oct4-EGFP expression when iPS cells were formed
with comparable reprogramming eﬃciency as skin
ﬁbroblast-derived iPS cells. These osteoblast-derived iPS
(O-iPS) cells exhibited gene expression proﬁles similar to
embryonic stem cells and formed teratomas comprising all
three germ layers after subcutaneous transplantation into
nude mice. Importantly, O-iPS cells gave rise to tissues that
were incorporated into the chimera embryos. Altogether,
these ﬁndings demonstrate that osteoblasts derived from
intramembranous bone can be reprogrammed into iPS cells,
which exhibit embryonic stem cell gene expression signatures
and features of pluripotency.
2. Materials and Methods
2.1. Mice and Fibroblasts. Mice were maintained in the
Laboratory Animal Unit of the University of Hong Kong.
All mouse studies were approved by the Committee on the
Use of Live Animals in Teaching and Research (CULATR)
and were done in accordance with institutional and interna-
tional standards and regulations. Osteoblasts were isolated
from calvariae of newbornmice carrying bothOsx1-GFP::Cre
and Oct4-EGFP. Oct4-EGFP transgenic mice serve as control.
The calvariae were digested with Dispase (Worthington
Biochemical Co.) and Collagenase II (Sigma) at 37°C for
5 minutes with rocking. After centrifugation for 5min at
2000 rpm, the cell pellet was resuspended in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Gibco) plus 10% fetal
bovine serum (BIOSERA) and seeded 1× 106 cells per
100× 20mm dish and cultured at 37°C.
Embryonic ﬁbroblasts were isolated from the C57BL/6N
mouse line derived from Charles River Lab, USA. The mouse
embryos at embryonic day E13.5 were dissected from the
uterus of a pregnant female mouse in 1× PBS, and heads
and internal organs were removed. Each embryo was coarsely
chopped by using a sterile razor blade and was digested with
0.25% trypsin (Invitrogen)/1mM EDTA (USB) for 20
minutes at 37°C. The reaction was stopped by adding
DMEM+10% FBS, and the medium was replaced the next
day. For dermal ﬁbroblast, after harvesting calvarial from
newborn mice, the dead newborn was washed with water
once, then with 70% ethanol twice. Ethanol was completely
removed. The mouse was cut on the dorsal side and along
the length of the body with a scalpel such that the skin is
cut but the internal parts of the body are intact. The skin
was carefully separated from the rest of the viscera and was
digested with 0.25% trypsin/1mM EDTA overnight at 4°C.
Forceps were used to separate the epidermis from the dermis,
which is further cut into small pieces, and a sterile glass cov-
erslip was placed over 10 skin pieces in the center of a 6-well
plate. A few drops of fresh DMEM+10% FBS medium were
added into the space below the coverslip followed by the
addition of fresh DMEM+10% FBS medium to the well.
Cells were cultured at 37°C for few days until conﬂuency,
and then the coverslips were removed.
2.2. Fluorescence-Activated Cell Sorting. Isolation of osteo-
blasts expressing GFP by ﬂuorescence-activated cell sorting
from four calvarial bones of newborn mice carrying Osx1-
GFP::Cre and Oct4-EGFP was performed as described in
Liu et al. [21]. Brieﬂy, osteoblasts derived from transgenic
strains were digested with 0.25% trypsin (Sigma)/1mM
EDTA (Thermo Fisher Scientiﬁc) for 10minutes at 37°C,
and the reaction was stopped by adding DMEM+10% FBS.
2× 106 cells were pelleted and resuspended in fresh DMEM
+10% FBS. Wild-type osteoblasts were used for calibrating
BD FACSAria I cell sorter before sorting GFP+ osteoblasts.
The sorted GFP+ osteoblasts (1× 104 cells per well) were
cultured in fresh DMEM+10% FBS medium at 37°C.
2.3. Alizarin Red S Staining. Osteoblasts were ﬁxed in 10%
formaldehyde in 1× PBS for 15mins, stained with 40mM
Alizarin Red S (Sigma) solution for 30 seconds to 5 minutes,
and washed 3 times with distilled water to remove excess
staining solution.
2.4. Quantitative RT-PCR. The expression levels of stem cell
and various lineage maker genes were quantiﬁed by real-
time RT-PCR. RNA was extracted from cells using RNAspin
Mini Kit (GE Healthcare) following the manufacture’s proto-
col. Total RNAs (2μg) were reverse-transcribed by using the
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Superscript III First-Strand Synthesis System (Invitrogen).
50 ng of cDNA with 0.2μM of each oligonucleotide primer
was mixed with Power SYBR Green PCR Master Mix
(Applied Biosystems) in a 25μl volume. The conditions were
programmed as follows: initial denaturation: 95°C, 1min
followed by 40 cycles of 15 s stage at 95°C and 30 s at 60°C,
then 15 s at 95°C, 1min at 60°C, and 15 s at 95°C. All of the
samples were triplicated, and level of transcripts from each
gene was normalized to endogenous Gapdh control. Primer
sequences are provided in Supplementary Table S1.
2.5. Generation of O-iPS and F-iPS Cells. 105 sorted cells were
infected with retrovirus generated from Plat-E cells, which
were transfected with pMXOct4 (id: 13366), pMXSox2 (id:
13367), pMXKlf4 (id: 13370), and pMXc-Myc (id: 13375)
(Addgene) in 6-well dishes with 0.5ml of each viral superna-
tant (total 2ml per well), and spun at 2500 rpm at 20°C for
90min. The reprogramming factor-infected osteoblasts were
cultured in osteoblast medium for 5 days before replating
8× 105 cells per 10 cm dish precoated with mitomycin C-
inactivated mouse embryonic ﬁbroblast in ES maintenance
media. Media were changed daily until ES-like colonies were
observed. F-iPS cells were generated from dermal ﬁbroblasts
of newborn mice. 106 ﬁbroblast cells were plated onto all
wells of a 6-well plate and spin-infected with the four viral
supernatants. Cells were cultured further in DMEM media
supplemented with 15% FBS, 1×penicillin/streptomycin/
glutamine (Invitrogen). On day 5, the cultured cells were
trypsinized and replated in four 10 cm dishes on mitomycin
C-inactivated mouse embryonic ﬁbroblast with ES mainte-
nance media. Media were changed every day until ES-like
colonies were observed.
2.6. Immunoﬂuorescence. iPS cells were grown on 8-well
chamber slides. Cells were ﬁxed in 4% paraformaldehyde
(Sigma) for 10min at room temperature (RT). Cells were
washed with 2× PBS. Cells were permeabilized with 0.2%
Triton X-100/PBS (PBST) for 10min at RT and were incu-
bated with blocking solution (1% BSA (USB)/PBST) for
30min at RT. Appropriate primary antibody solution diluted
in blocking solution was applied onto the slide and incubated
overnight at 4°C. Cells were washed twice with PBS followed
by incubating with appropriate secondary antibody diluted
in blocking solution for 2 hours in darkness at RT. Cells
were washed 3× with PBS. The last wash was aspirated, and
a drop of VECTASHIELD® HardSet™ Mounting Medium
with DAPI (Vector) was applied, and the slide was mounted
with coverslip.
2.7. Genotyping of O-iPS Colonies. After being digested with
0.25% trypsin/1mM EDTA, iPS cells were pelleted, resus-
pended, and digested in 100μl 1×TNE supplemented with
0.2mg/ml Proteinase K for 16h at 65°C. Then equal volume
of phenol/isoamyl alcohol/chloroform (25 : 1 : 24, USB) was
added into the mixture and centrifuged at full speed for
10min. The upper aqueous phase was transferred to a
1.5ml fresh eppendorf tube. One milliliter of prechilled abso-
lute ethanol was added into the solution and centrifuged at
full speed for 10min. The DNA pellet was washed in cold
70% ethanol followed by centrifugation to remove the etha-
nol. After 10min air dry, the pellet was resuspended in
20μl ddH2O.
2.8. Teratoma and Chimera Analysis. Prior to transplanta-
tion, O-iPS colonies were dissociated into single cell sus-
pensions to enable transplantation of deﬁned numbers of
cells. Teratomas were assessed by injecting 106 cells subcu-
taneously into the dorsal ﬂank of nude mice, and teratoma
formation was monitored for 4 weeks after injection. Col-
lected tumors were processed for hematoxylin and eosin
(H&E) staining. Chimera analysis was conducted by inject-
ing Oct4-EGFP+ O-iPS cells into blastocysts isolated from
C57BL/6 embryos, which were collected at the two-cell
stage. The fertilized embryo was collected from the oviduct
and cultured in KSOM media. The reconstituted blasto-
cysts were implanted into 2.5-day pseudopregnant ICR
females. Embryos were harvested at E17.5, and their tails
were subjected to PCR genotyping with primers speciﬁc
for Oct4-EGFP, Cre, and retroviral vectors carrying Oct4,
Sox2, and Klf4 genes.
2.9. Statistical Analysis. All analyses were performed in
triplicate for n = 3 at least. Real-time RT-PCR was also
performed at least 3 times. Data are expressed as aver-
age ±SEM, and the statistical signiﬁcance (p value) was
determined by a two-tailed Student’s t-test using Graph-
Pad Prism 6.
3. Results
3.1. Isolation and Characterization of Osteoblasts from
Calvarial Bone. To isolate an enriched population of osteo-
blasts for iPS reprogramming, we crossed Osx1-GFP::Cre
with Oct4-EGFP transgenic mouse lines [22, 23] and ana-
lyzed 4 out of 8 neonatal mice that showed the presence of
both Oct4-EGFP and Cre transgenes in their genome after
genotyping analysis (Figure 1(a)). Osx1-GFP::Cre is a BAC
transgenic mouse line in which expression of a Tet-oﬀ regu-
latable GFP::Cre fusion protein is placed under the transcrip-
tional regulation of the Osx1 promoter that is active in
osteoblast precursor cells [22]. Oct4 is an important marker
of the undiﬀerentiated state and a central regulator of pluri-
potency in embryonic stem cells (ESCs) [24–26]. Therefore,
Oct4-EGFP transgenic mouse served as a reporter for the for-
mation of iPSCs, which express EGFP under control of an
Oct4 18 kb genomic fragment containing the minimal pro-
moter and proximal and distal enhancer [23]. We ﬁrst iso-
lated osteoblasts expressing GFP by ﬂuorescence-activated
cell sorting (FACS) from 4 calvarial bone of newborn mice
harboring both transgenes, whereas no GFP expression was
observed in calvarial bone derived from Oct4-EGFP trans-
genic mice. Upon plating, more than 90% osteoblasts showed
GFP expression (Figure 1(b)). qPCR analyses revealed that
GFP+ osteoblasts expressed high levels of characteristic
markers Runx2, Osterix, Col1a1, and osteocalcin and low
levels of Klf4 and c-Myc transcripts whereas expression of
markers for chondrocytes (Sox9 and Col2a1) and ESC
markers (Oct4, Sox2, and c-Myc) were low. In contrast,
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unsorted osteoblasts expressed Sox9 and Col2a1 in addition
to osteoblast markers (Figure 1(c)). In addition, the majority
of sorted GFP+ cells were positive for Alizarin Red S staining
indicating that they are functional osteoblasts undergoing
mineralization (Figure 1(d)). These results indicate that
sorted GFP+ cells derived from calvarial bone contain
homogenous population of functional osteoblasts without
containing other cell types such as chondrocytes and ESCs.
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Figure 1: Isolation and characterization of calvaria-derived osteoblasts from newborn mice carrying both Osx1-Cre::GFP and Oct4-EGFP
transgenes. (a) Genotyping analysis of 8 neonatal mice carrying Osx1-GFP::Cre and Oct4-EGFP transgenes for coding regions of Oct4-
EGFP and Cre. (b) Bright ﬁeld images of the newborn calvaria. No GFP expression was detected in Oct4-EGFP calvaria, whereas GFP
expression was observed in calvaria isolated from a transgenic mouse carrying both Osx1-GFP::Cre and Oct4-EGFP. Representative FACS
plot of isolating osteoblasts expressing GFP from calvarial bone. Sorted osteoblasts express GFP in culture. Inset shows phase image of
sorted osteoblasts. Scale bars: 20 μm for calvarial bone; 5 μm for GFP+ cells. (c) qPCR analysis of the indicated transcript levels in MSCs,
ESCs, unsorted osteoblasts, and sorted GFP+ osteoblasts. Individual mRNA expression levels were normalized to Gapdh with fold change
relative to dermal ﬁbroblasts, which is arbitrary set to 1. (d) From left to right: phase image of sorted osteoblasts. GFP+ osteoblasts were
positive for Alizarin Red S staining. Scale bar: 20μm. Three independent experiments are represented in (c). Data are expressed as
means ± SEM. ∗p < 0 05; ∗∗p < 0 01; ∗∗∗p < 0 001.
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3.2. Reprogramming of Osteoblasts into iPS Cells. Since sorted
osteoblasts expressed low levels of Klf4 and c-Myc that might
not be suﬃcient to induce iPS reprogramming with other
Yamanaka factors (Sox2 and Oct4), we used all four repro-
gramming factors to transduce 4× 104 GFP+ osteoblasts
using retroviruses. After culture of retroviral-transduced
osteoblasts in growth medium for 6 days, they were trans-
ferred and cultivated onto the feeder layer comprising mouse
embryonic ﬁbroblasts in ES medium and daily monitored
for the appearance of Oct4-EGFP+ ES-like colonies. We
observed iPS-like colonies on day 22 posttransduction, a
time when iPS reprogramming is expected to be com-
pleted [27] (Figure 2(a)). Since somatic gene expression
is subjected to epigenetic silencing during the course of
iPS reprogramming [28], we anticipated that silencing of
Osx1 promoter driving GFP expression could occur prior
to completion of reprogramming, which activates Oct4-
EGFP expression in iPS cells. We used osteoblasts derived
from Osx1-GFP::Cre transgenic mice without Oct4-EGFP
transgene as a control to determine at what time point
the GFP expression driven by Osx1 promoter is silenced.
In addition, skin ﬁbroblasts isolated from single and dou-
ble transgenic mice at newborn stage were used for com-
paring the eﬃciency of iPS cells generation with sorted
osteoblasts. We found that GFP expression in osteoblasts
derived from Osx1-GFP::Cre/Oct4-EGFP and Osx1-GFP::Cre
transgenic mice was diminished on day 3 and completely lost
on day 4 posttransduction, whereas GFP expression was only
d0
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Figure 2: Reprogramming of osteoblasts into iPS cells. (a) Schematic illustration of iPS reprogramming strategy from sorted osteoblasts. (b)
Phase (insets) and ﬂuorescence images of osteoblasts and ﬁbroblasts derived from transgenic mice carryingOsx1-GFP::Cre and/orOct4-EGFP
as well as their respective iPS cells at the indicated day (d) posttransduction. Scale bar: 5 μm. (c) Quantiﬁcation of the number of Oct4-EGFP+
F-iPS and O-iPS colonies formed. n = 3. Data are expressed as means ± SEM. (d) Genotyping of 6 O-iPS colonies for the presence of Oct4-
EGFP and Cre transgenes. Sorted GFP+ osteoblasts serve as a positive control and blank as a negative control.
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Figure 3: Continued.
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initiated and observed in iPS-like colonies harboring both
transgenes from day 15 onward (Figure 2(b)), indicating that
GFP expression detected was derived from activation of
Oct4-EGFP transgene in iPS cells. While GFP expression
was not detected in transduced ﬁbroblasts derived from
Osx1-GFP::Cre/Oct4-EGFP and Osx1-GFP::Cre transgenes
as expected, we observed similar dynamics for the activation
of GFP expression in ﬁbroblast-derived iPS (F-iPS) cells
carrying both transgenes or Oct4-EGFP alone as observed
in osteoblasts (Figure 2(b)). Both osteoblast- and ﬁbroblast-
derived iPS cells exhibited comparable reprogramming eﬃ-
ciency (0.1075%/0.1175%; Figure 2(c)). To further examine
whether iPS colonies were originated from Osx1-GFP::Cre/
Oct4-EGFP-derived osteoblasts, we manually picked 6 indi-
vidual colony to determine the presence of Oct4-EGFP and
Cre transgenes in their genome by PCR. Sorted GFP+ osteo-
blasts and blank served as positive and negative control,
respectively. Genotyping analysis showed that the coding
regions of Oct4-EGFP and Cre were detectable in the genome
of 6 iPS-like colonies (Figure 2(d)), conﬁrming that they are
originally derived from osteoblasts carrying both transgenes.
We therefore named them as osteoblast-derived iPS (O-iPS)
cells. Taken together, these ﬁndings suggest that loss of
GFP expression in osteoblasts at the initial phase of iPS
reprogramming could be due to epigenetic silencing of
Osx1 promoter activity by Yamanaka factors and subsequent
emergence of GFP expression in O-iPS cells was derived from
transcriptional activation of Oct4 promoter. Consistent with
this notion, exogenous expression of four reprogramming
factors was silenced or barely detectable in O-iPS clones
indicating completion of iPS reprogramming (Figure S1).
3.3. Molecular Characterization of O-iPS Colonies. Previous
studies showed that F-iPS colonies expressed ESC markers
[8]. To examine whether O-iPS colonies also exhibited gene
expression proﬁles characteristic of ESCs, we manually
picked 3 O-iPS and 3 F-iPS colonies to compare their levels
of ESC marker gene expression by qPCR. ESCs served as a
positive control, whereas MSCs, ﬁbroblasts, and GFP+ osteo-
blasts as negative controls. The results showed that 3 individ-
ual O-iPS clones expressed comparable levels of ES makers
(Oct4, Sox2, Klf4, c-Myc, Nanog, Utf1, Fgf4, Esg1, Gdf3,
Zfp296, Cripto, Dax1, Neo, and Nat1) with F-iPS clones and
ESCs. Interestingly, we also detected signiﬁcant levels of
Neo and Nat1 transcripts in GFP+ osteoblasts (Figures 3(a)
and 3(b)). In addition, immunoﬂuorescence showed that
both O-iPS and F-iPS cells were positive for SSEA1 and
OCT4 (Figure 3(c)). Consistent with previous observations
[29], silencing retroviral-mediated expression of reprogram-
ming factors correlated with the establishment of O-iPS cells
(Figure S1). Collectively, these results demonstrate that like
F-iPS, O-iPS clones also express signature genes characteris-
tic of ESCs (Figure 3(b)).
3.4. Pluripotent Potential of O-iPS Cells. To examine whether
O-iPS colonies possessed pluripotent potential, we selected
6 O-iPS colonies (O-iPS C6, O-iPS C7, O-iPS C8, O-iPS
C9, O-iPS C10, and O-iPS C11) and injected 106 cells per
clone subcutaneously into the dorsal ﬂank of nude mice.
After 4 weeks of injection, all of themwere capable of forming
teratomas in which small patches of GFP+ cells were observed
indicating that O-iPS clone could diﬀerentiate into the osteo-
blastic lineage accompanied with activation of Osx1-GFP
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Figure 3: Gene expression proﬁles of O-iPS cells. (a) qPCR analysis for the indicted transcript levels in 3 F-iPS clones, 3 O-iPS clones, sorted
GFP+ osteoblasts, ESCs, and MSCs. Individual mRNA expression levels were normalized to Gapdh with fold change relative to dermal
ﬁbroblasts which is arbitrary set to 1. (b) Heatmap of log fold change (Log2 FC) values for expression levels of the indicated transcripts in
ﬁbroblasts, MSCs, ESCs, GFP+ osteoblasts, F-iPS, and O-iPS clones. (c) Immunoﬂuorescence of ESCs, O-iPS clone 6, and F-iPS clone 4 for
antibodies against SSEA1 and OCT4. Scale bar: 100μm. Three independent experiments are represented in (a). Data are expressed as
means ± SEM. ∗∗p < 0 01; ∗∗∗p < 0 001.
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Figure 4: Pluripotent potential of O-iPS cells. (a) Formation of two teratomas derived from O-iPS6 cells under the skin in nude mice 4 weeks
posttransplantation. Inset shows the size of teratomas harvested from nude mice. Teratomas derived from 5 diﬀerent O-iPS cells and ESC-
derived teratoma serves as a positive control. GFP expression was detected in an O-iPS6-derived teratoma. Scale bar: 1 cm. (b) Genotyping
of teratoma tissues derived from 6 O-iPS colonies for Cre transgene. Sorted GFP+ osteoblasts serve as a positive control. (c) H&E staining
of teratoma sections showed diﬀerentiation of O-iPS6 into various tissues from all three germ layers. CNS: central nervous system. Scale
bar: 100 μm. (d) Genotyping of coding regions for Oct4-EGFP, Cre, and integrated retroviral vectors carrying reprogramming factor genes
(Oct4, Sox2, and Klf4) on tail tissues derived from E17.5 chimera embryos. ESCs serve as a negative control. Sorted GFP+ osteoblasts and
retroviral vectors carrying reprogramming factors serve as positive controls.
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expression while Oct4-EGFP expression was silenced upon
osteogenic diﬀerentiation (Figure 4(a)). Genotyping of Cre
gene indicated that teratoma tissues were derived from O-
iPS cells (Figure 4(b)). Detailed morphological analyses fur-
ther revealed that teratoma was composed of tissues derived
from all three germ layers including muscle, adipose, gut epi-
thelial, and central nervous system (Figure 4(c)). Therefore,
these teratoma studies demonstrate that O-iPS cells pos-
sessed pluripotent potential.
We then performed chimera assay to further interrogate
the pluripotency of O-iPS clone. We selected O-iPS C6 clone
for injection into ICR-derived blastocyst. Genotyping analy-
sis of the DNA extracted from the tail of chimera embryos
revealed that 3 out of 10 embryos at E17.5 harbored Oct4-
EGFP and Cre transgenes as well as sequences of retroviral
vector carrying Oct4, Sox2, and Klf4 genes (Figure 4(d)).
These results suggest that O-iPS C6 clone contributed to
some tissue formation in the tails of chimera embryos. Collec-
tively, our ﬁndings show that O-iPS cells exhibit pluripotent
features with ability to form teratomas and chimera embryos.
4. Discussion
In 2006, Shinya Yamanaka announced a milestone ﬁnding
that iPS cells can be derived from skin ﬁbroblasts by
retroviral-mediated expression of two pluripotent transcrip-
tion factors, Oct4 and Sox2, and two proto-oncogenes, Klf4
and c-Myc (OSKM) [8]. These scientiﬁc breakthroughs have
revolutionized our view about cellular plasticity that lineage
committed or terminally diﬀerentiated cells can be repro-
grammed into pluripotent state. This notion is further sup-
ported by numerous follow-up studies in which many
diﬀerent cell types from a wide range of species can be repro-
grammed to pluripotency by ectopic expression of OSKM
[30]. A recent report demonstrated that human osteoblasts
derived from iliac crest bone, which is generated from endo-
chondrial ossiﬁcation, can be converted into iPS cells (hOB-
iPSCs) [20]. In this study, osteoblasts were isolated as they
emerged from the human bone chips in growth media. How-
ever, the homogeneity of osteoblast population extracted by
this crude preparation remains questionable and the assess-
ment of iPS cell identity was mainly based on cell mor-
phology, markers analysis, and in vitro diﬀerentiation
assays. Here we reported a more rigorous approach by
taking advantage of mice carrying both Osx1-GFP::Cre
and Oct4-EGFP transgenes as reporters that allowed us
to isolate homogenous population of osteoblasts from cal-
varial intramembranous bone by FACS as evidenced by
expression of characteristic osteoblast markers compared to
unsorted population, which expressed chondrocyte makers
Sox9 and Col2. In addition, the dynamics of reprogramming
process from sorted osteoblasts to iPS cells can be monitored
on a daily basis, and we observed a rapid silencing of Osx1-
GFP expression after 3 days of reprogramming followed
by late activation of pluripotent Oct4-EGFP expression.
This is consistent with the idea that iPS reprogramming
is a stepwise process involving transcriptional and epige-
netic changes that cause downregulation of somatic gene
expression (Osx1-GFP) and then transition to a state that
is positive for the embryonic marker SSEA1 and, ﬁnally,
induce the full pluripotency network (Oct4-EGFP) [31, 32].
Although the starting osteoblast population exhibited
homogenous expression of Osx1-GFP, random integration
of retroviruses results in diﬀerent expression levels of each
individual factor, which induced stochastic gene expression
changes in the host cells that confer only a fraction of osteo-
blasts with the right levels of transgenes expression to pro-
ceed with the correct transition of reprogramming events
[33]. Failure to transition through any one of these steps
(e.g., unable to silence Osx1-GFP expression) would lead to
a block in reprogramming that account for the low overall
reprogramming eﬃciency. Consistent with this model, sev-
eral intermediate cell types exist at diﬀerent stages of repro-
gramming, and some of these intermediates are still plastic
and can be reverted to the early reprogramming state even
if they already express marker of pluripotency SSEA1 [34].
Further analysis of these intermediates revealed transient
activation of genes associated with progenitor state of the
starting cell population that follows a reversal of cell lineage
development during iPS or lineage reprogramming [35].
Whether calvarial osteoblasts could be reprogrammed via
neural crest lineage as intermediates before pluripotency
remains to be determined. Nevertheless, successful O-iPS
generation indicates that the stages of partial reprogrammed
cells with transient fates have been passed that require con-
tinuous OSKM expression at the early stage and silencing
of their expression later in reprogramming is a prerequisite
for these cells to become more committed to the pluripotent
state [32].
Previous in vitro studies showed that hOB-iPS cells were
able to diﬀerentiate into ectodermal and mesodermal cell
types but not endodermal lineage. In contrast, we provided
in vivo evidence that O-iPS cells gave rise to teratomas
containing tissues derived from all three embryonic germ
layers including induction of osteoblast lineage and also
contributed to some tissue formation in chimera embryos,
indicating that O-iPS cells are pluripotent. Importantly,
tissues from teratomas and chimera embryos carried both
Osx1-GFP::Cre and Oct4-GFP transgenes integrated into
the genome conﬁrming of their osteoblast origin and also
reﬂecting the power of our approach using transgenic mice
to follow the progression of osteoblast reprogramming into
iPS cells not only in vitro but also in vivo.
In summary, using Osx1-GFP::Cre and Oct4-EGFP trans-
genic mice, we demonstrate the ability to monitor stepwise
reprogramming process from enriched population of intra-
membranous osteoblasts into iPS cells. These O-iPS cells
exhibit stem cell-like gene expression signature and features
of pluripotency. Considering neural crest origin of intra-
membranous osteoblasts, our study allows us to further
investigate whether multipotent neural crest cells can be
formed and enriched as intermediate during iPS reprogram-
ming for therapeutic use in the future.
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and c-Myc transcript levels. Individual mRNA expression
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